Dr. Robert Doebele, M.D., Ph.D.

Dr. Doebele is a physician-scientist and medical oncologist experienced in bringing biology-based and tumor-agnostic treatment approaches to patients. Prior to joining Boundless Bio, Dr. Doebele served as Chief Medical Officer and Chief Scientific Officer at Rain Oncology, a publicly traded, clinical-stage precision oncology company acquired by Pathos AI.  Prior to Rain, he was an Associate Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus where he also served as the Director of the Thoracic Oncology Research Initiative and co-Director of the Molecular Tumor Board at the University of Colorado Cancer Center. Dr. Doebele led the research at the University of Colorado that launched the TRK field by demonstrating that that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approvals of Vitrakvi^TM and Rozyltrek^TM.

Dr. Doebele received his AB in Molecular Biology from Princeton University and received his MD and PhD in Immunology from the University of Pennsylvania. He conducted his internal medicine residency and a medical oncology fellowship at the University of Chicago.